2016
Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.
Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. DOI: 10.1200/jco.2016.34.2_suppl.252.Peer-Reviewed Original ResearchResidual tumor fociMesenchymal growth factorsRadical prostatectomy specimensClonal heterogeneityTumor initiating cellsProstate cancer organoidsMechanisms of resistanceMetastatic PCPC progressionTherapeutic alternativeTumor fociNormal epitheliumPatient stem cellsProstatectomy specimensMolecular alterationsPotential efficacyCancer organoidsSelf-renewal capacityInitiating cellsGrowth factorBiologic responseEarly passagesGrowth inhibitionStem cellsEpigenetic alterations
2010
Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling Pathways*
Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Kim I. Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling Pathways*. Journal Of Biological Chemistry 2010, 285: 39401-39408. PMID: 20889504, PMCID: PMC2998138, DOI: 10.1074/jbc.m110.103705.Peer-Reviewed Original ResearchConceptsBone morphogenetic protein 6BMP receptor type IIProtein 6Activin-like kinase 2Non-Smad pathwaysTranscription factor GATA4P38 Signaling PathwayTarget genesKnockdown experimentsKinase 2Signaling pathwaysSignaling mechanismReceptor type IISmadIntracellular levelsIL-6 inductionPathwayGrowth factorInductionExpressionInterleukin-6 expressionTranscriptionMacrophagesGenesGATA4
2006
Role of bone morphogenetic proteins in transitional cell carcinoma cells
Kim I, Kim S. Role of bone morphogenetic proteins in transitional cell carcinoma cells. Cancer Letters 2006, 241: 118-123. PMID: 16500023, DOI: 10.1016/j.canlet.2005.10.009.Peer-Reviewed Original Research
2005
Transforming Growth Factor-β: Biology and Clinical Relevance
Kim I, Kim M, Kim S. Transforming Growth Factor-β: Biology and Clinical Relevance. BMB Reports 2005, 38: 1-8. PMID: 15715939, DOI: 10.5483/bmbrep.2005.38.1.001.Peer-Reviewed Original Research
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPredictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder
Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaBladder transitional cell carcinomaInvasive tumor stageOverexpression of TGFDisease progressionIndependent predictorsCell carcinomaTumor stageLoss of expressionTGF betaGrowth factorDisease-specific survivalAltered expressionExpression of TGFGrowth factor-β1Lymphovascular invasionRadical cystectomySpecific survivalClinical outcomesCystectomy specimensUrinary bladderImmunohistochemical stainingBlinded fashionFactor-β1Predictive valuePreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status
1996
Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP
Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.Peer-Reviewed Original ResearchConceptsDoses of dihydrotestosteroneProstatic cancer cell linesLNCaP cellsCancer cell linesTGF-beta1 messenger RNART-PCRCompetitive quantitative RT-PCRTGF-beta1 proteinDose-dependent increaseGrowth arrestEnzyme-linked immunoadsorbent assayCell linesTGF-beta1 neutralizing antibodyActivation of latentDose-response curveMessenger RNALNCaP proliferationQuantitative RT-PCRWestern blot analysisNeutralizing antibodiesLinear dose-response curveHigh doseTGF-beta1Immunoadsorbent assayGrowth factor